Inhibition of the PDE4 family has been shown to ameliorate metabolic and inflammatory disorders such as steatohepatitis, liver fibrosis, type 2 diabetes, and atherosclerosis in rodent models (23, 24, 30–33). This evidence concerns the gene PDE4A and Hepatic fibrosis.